The 3 analysts offering 12-month price forecasts for VistaGen Therapeutics Inc have a median target of 8.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +253.98% increase from the last price of 2.26.
The current consensus among 4 polled investment analysts is to Buy stock in VistaGen Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.06
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.